• News
  • SAN DIEGO
  • BioTech

Halozyme inks drug development deal with Pfizer

Halozyme Therapeutics Inc. said Friday it has reached an agreement with Pfizer to develop injectable versions of the drugmaker's biotech drugs.

San Diego-based Halozyme (Nasdaq: HALO) specializes in a recombinant hyaluronidase enzyme technology, which is designed to temporarily break down a substance in the body that forms a barrier between cells so drugs can be absorbed faster. That would allow some drugs to be delivered by an injection instead of an IV drip.

Under the terms of the agreement, Halozyme has granted to Pfizer (NYSE: PFE), based in New York, a license to develop and release up to six products using its enzyme technology. Halozyme will receive an initial payment of $8 million, which includes the upfront fee for exclusive licenses to two specified drugs in primary care and specialty care, and the right for Pfizer to choose up to four additional targets after additional payments.

Halozyme is entitled to additional payments of up to $507 million if Pfizer's products reach certain regulatory and sales milestones. The company is also entitled to additional royalty payments on sales of the drugs.

Shares of Halozyme surged 27 percent, or $1.49, to close at $7.01 Friday.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.